The import value of insulin to China is anticipated to rise steadily from 2024 through 2028, showing a gradual increase each year. In 2024, the import value is forecasted at $939.54 million USD and grows to $1105.8 million USD by 2028. This steady rise indicates a compound annual growth rate (CAGR) over the five-year period. Unfortunately, the data for 2023 is not provided for comparison, thus actual percentage changes from that year cannot be calculated. However, consistent year-on-year rises suggest robust demand and potential market expansion.
Future trends to watch for include:
- Changes in domestic production capacity of insulin in China, which could impact import levels.
- The development of healthcare policies impacting diabetes treatment, potentially affecting insulin demand.
- Advancements in biotechnology possibly leading to alternative diabetes treatments that could alter insulin market dynamics.
